This HTML5 document contains 16 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
rdfshttp://www.w3.org/2000/01/rdf-schema#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
ncihttp://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
nci:C2103
rdf:type
owl:Class
rdfs:label
I 131 Monoclonal Antibody Lym-1
rdfs:subClassOf
nci:C1511
nci:P106
Amino Acid, Peptide, or Protein Immunologic Factor
nci:P108
I 131 Monoclonal Antibody Lym-1
nci:P207
C1134561
nci:P303
Aggressive B-cell Lymphoma; Previously Treated Diffuse Large Cell Lymphoma; Intermediate or High Grade Recurrent or Refractory B-cell Non-Hodgkins Lymphoma.
nci:P329
38533
nci:P330
38533
nci:P366
I_131_Monoclonal_Antibody_Lym-1
nci:P90
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Oncolym</n0:term-name><n0:term-group>BR</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Iodine I 131 Monoclonal Antibody Lym-1</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>I 131 Monoclonal Antibody Lym-1</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A radioimmunoconjugate of a murine monoclonal antibody, MoAb Lym-1, labeled with iodine 131 (I-131). MoAb Lym-1 recognizes an epitope of the histocompatibility antigen HLA-DR, which is over-expressed on most B-cell lymphomas. I-131 MoAb Lym-1 delivers beta and gamma radiation emitting I-131 nuclide directly to tumor cells that express HLA-DR, thereby allowing imaging and/or treatment of cancers.</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code
C2103